GLP-1 receptor agonists have become the fastest-adopted drug class in pharmaceutical history, and their consequences extend far beyond healthcare.
📈 What changed: Eli Lilly's retatrutide (triple GIP/GLP-1/glucagon agonist) posted positive Phase 3 topline data on 23 Jul 2026: TRIUMPH-2 (obesity + type 2 diabetes) showed up to 20.8% weight lo…
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 82/100 | Direct pharma: commercial; consumer disruption: early signal. |
| Evidence Strength higher is better · high confidence | 71/100 | Phase 3 data robust; consumer scanner data now confirming. |
| Commercial Proximity higher is better · high confidence | 78/100 | $18B market growing now; oral launch imminent. |
| Capital & Policy Support higher is better · high confidence | 57/100 | Medicare coverage begins mid-2026; state Medicaid adoption option. |
| Crowding Risk lower is better · high confidence | 78/100 | Heavily covered by analysts; risk in consensus; disrupted-sector risk may be underpriced. |
| Reflexivity Risk lower is better · medium confidence | 33/100 | Pharma driven by data; consumer disruption more narrative-driven. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 16 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.